A Plus Biotechnology Co (TPE:6918) Beneish M-Score: -1.53 (As of Jul. 08, 2026)


TPE:6918 A Plus Biotechnology Co Ltd TPE:6918
71 GF Score
Price NT$74.30
GF Value NT$87.15
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is A Plus Biotechnology Co Beneish M-Score?

A Plus Biotechnology Co TPE:6918 -1.59% 71 Beneish M-Score is -1.53 as of Jul. 08, 2026. GuruFocus rates TPE:6918 with a GF Score™ of 71/100 and a GF Value™ of NT$87.15 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 763 Medical Devices & Instruments companies, A Plus Biotechnology Co ranks worse than 87.68% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.53 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for A Plus Biotechnology Co's Beneish M-Score or its related term are showing as below:

TPE:6918' s Beneish M-Score Range Over the Past 10 Years
Min: -2.02   Med: -1.78   Max: -1.53
Current: -1.53

During the past 7 years, the highest Beneish M-Score of A Plus Biotechnology Co was -1.53. The lowest was -2.02. And the median was -1.78.


A Plus Biotechnology Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for A Plus Biotechnology Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A Plus Biotechnology Co Beneish M-Score Chart

A Plus Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.00 0.00 -2.02 -1.53

A Plus Biotechnology Co Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.02 0.00 -2.71 -2.29 -1.53

TPE:6918 vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, A Plus Biotechnology Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


A Plus Biotechnology Co Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where A Plus Biotechnology Co's Beneish M-Score falls into.


TPE:6918
71GF Score
A Plus Biotechnology Co Ltd TPE:6918
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

A Plus Biotechnology Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of A Plus Biotechnology Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8906+0.528 * 1.0129+0.404 * 3.1708+0.892 * 1.0861+0.115 * 0.953
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9789+4.679 * 0.006755-0.327 * 0.8298
=-1.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$178.5 Mil.
Revenue was 214.913 + 210.695 + 213.896 + 196.387 = NT$835.9 Mil.
Gross Profit was 141.912 + 144.453 + 146.259 + 140.834 = NT$573.5 Mil.
Total Current Assets was NT$1,187.1 Mil.
Total Assets was NT$1,550.0 Mil.
Property, Plant and Equipment(Net PPE) was NT$243.8 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$27.2 Mil.
Selling, General, & Admin. Expense(SGA) was NT$318.1 Mil.
Total Current Liabilities was NT$198.1 Mil.
Long-Term Debt & Capital Lease Obligation was NT$83.0 Mil.
Net Income was 38.991 + 43.401 + 43.365 + 43.625 = NT$169.4 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0.0 Mil.
Cash Flow from Operations was 56.715 + 11.021 + 39.405 + 51.771 = NT$158.9 Mil.
Total Receivables was NT$184.5 Mil.
Revenue was 204.541 + 200.27 + 186.855 + 177.925 = NT$769.6 Mil.
Gross Profit was 142.423 + 134.03 + 132.819 + 125.506 = NT$534.8 Mil.
Total Current Assets was NT$896.8 Mil.
Total Assets was NT$1,177.3 Mil.
Property, Plant and Equipment(Net PPE) was NT$251.9 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$26.7 Mil.
Selling, General, & Admin. Expense(SGA) was NT$299.2 Mil.
Total Current Liabilities was NT$163.3 Mil.
Long-Term Debt & Capital Lease Obligation was NT$94.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(178.503 / 835.891) / (184.534 / 769.591)
=0.213548 / 0.239782
=0.8906

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(534.778 / 769.591) / (573.458 / 835.891)
=0.694886 / 0.686044
=1.0129

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1187.061 + 243.75) / 1549.999) / (1 - (896.849 + 251.914) / 1177.314)
=0.076896 / 0.024251
=3.1708

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=835.891 / 769.591
=1.0861

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(26.697 / (26.697 + 251.914)) / (27.247 / (27.247 + 243.75))
=0.095822 / 0.100544
=0.953

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(318.057 / 835.891) / (299.153 / 769.591)
=0.380501 / 0.388717
=0.9789

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((83.001 + 198.133) / 1549.999) / ((94.016 + 163.309) / 1177.314)
=0.181377 / 0.21857
=0.8298

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(169.382 - 0 - 158.912) / 1549.999
=0.006755

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

A Plus Biotechnology Co has a M-score of -1.53 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.53 mean?
A Plus Biotechnology Co (TPE:6918) has a Beneish M-Score of -1.53 as of Jul. 08, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on A Plus Biotechnology Co and its competitors. According to the industry distribution chart, A Plus Biotechnology Co ranks #669 out of 763 companies in the Medical Devices & Instruments industry, placing it in the top 87.7%.
Is A Plus Biotechnology Co's Beneish M-Score too high?
A Plus Biotechnology Co's current Beneish M-Score is -1.53. Based on the distribution chart, A Plus Biotechnology Co ranks #669 out of 763 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, A Plus Biotechnology Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, A Plus Biotechnology Co ranks #669 out of 763 companies for Beneish M-Score. This places A Plus Biotechnology Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on A Plus Biotechnology Co and its competitors. A Plus Biotechnology Co's current Beneish M-Score is -1.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.15, compared to a current price of NT$74.30 — trading 14.7% below its estimated fair value. The current Beneish M-Score is -1.53. A Plus Biotechnology Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current Beneish M-Score is -1.53 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?

Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued. The current stock price of NT$74.30 is trading 14.7% below its estimated GF Value™ of NT$87.15. GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.

Key valuation signals for TPE:6918:

  • Beneish M-Score: -1.53
  • GF Value™: NT$87.15 vs. price of NT$74.30 (14.7% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


A Plus Biotechnology Co Business Description

Address No. 21, Qiaohe Road, 3rd Floor, Zhonghe District, New Taipei City, TWN
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
71GF Score

Get the complete analysis for TPE:6918

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$74.30
Price
NT$87.15
GF Value